68 related articles for article (PubMed ID: 36568792)
1. Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer.
Lin YT; Wang C; He XY; Yao QM; Chen J
Front Immunol; 2023; 14():1345942. PubMed ID: 38274823
[TBL] [Abstract][Full Text] [Related]
2. Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan.
Kashiwa M
Eur J Health Econ; 2024 Apr; 25(3):459-470. PubMed ID: 37261572
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy.
Mfumbilwa ZA; Simons MJHG; Ramaekers B; Retèl VP; Mankor JM; Groen HJM; Aerts JGJV; Joore M; Wilschut JA; Coupé VMH
Pharmacoeconomics; 2024 Apr; 42(4):419-434. PubMed ID: 38194023
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score.
Leone AG; Petrelli F; Ghidini A; Raimondi A; Smyth EC; Pietrantonio F
ESMO Open; 2022 Feb; 7(1):100380. PubMed ID: 35093742
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan.
Morimoto K; Moriwaki K; Shimozuma K; Nakayama T
J Gastroenterol; 2023 Dec; 58(12):1188-1197. PubMed ID: 37725256
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness analysis of the combination of serplulimab with chemotherapy for advanced esophageal squamous cell carcinoma: insights from the ASTRUM-007 trial.
Li J; Xu C; Yuan S
Cost Eff Resour Alloc; 2024 Jan; 22(1):8. PubMed ID: 38281053
[TBL] [Abstract][Full Text] [Related]
7. High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis.
Hur C; Choi SE; Kong CY; Wang GQ; Xu H; Polydorides AD; Xue LY; Perzan KE; Tramontano AC; Richards-Kortum RR; Anandasabapathy S
World J Gastroenterol; 2015 May; 21(18):5513-23. PubMed ID: 25987774
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer.
Huo G; Song Y; Chen P
J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38606826
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma.
Högner A; Thuss-Patience P
Pharmaceuticals (Basel); 2021 Feb; 14(2):. PubMed ID: 33673374
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study.
Park S; Lee Y; Lee J; Min YW; Kim HK; Choi JY; Jung HA; Choi YS; Choi YL; Shim YM; Sun JM
Cancer Res Treat; 2024 Apr; 56(2):567-579. PubMed ID: 37846467
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation.
Yamamoto K; Yamamoto S; Kato K
Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38676380
[TBL] [Abstract][Full Text] [Related]
12. LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma.
Sun JM; Adenis A; C Enzinger P; Shah MA; Kato K; Bennouna J; Doi T; Hawk NN; Yu L; Shah S; Bhagia P; Shen L
Future Oncol; 2024 May; ():. PubMed ID: 38695479
[TBL] [Abstract][Full Text] [Related]
13. Durable pembrolizumab response in metastatic MSS ARID1A-mutant undifferentiated carcinoma of the esophagus.
Ijaz Z; Kahramangil D; Gera K; Sahin I
J Chemother; 2024 May; ():1-6. PubMed ID: 38752926
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab dramatically resolves choroidal metastatis from esophageal adenocarcinoma and restores vision: a case report.
Barrett D; Sumnicht A; Chalam KV; Rauser M
Oxf Med Case Reports; 2021 Jun; 2021(6):omab047. PubMed ID: 34158961
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
Liu S; Jiang N; Dou L; Li S
Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
He C; Mi X; Xu G; Xu X; Xin W; Zhong L; Zhu J; Shu Q; Fang L; Ding H
PLoS One; 2024; 19(5):e0302961. PubMed ID: 38748691
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States.
Huo G; Song Y; Liu W; Cao X; Chen P
Front Pharmacol; 2024; 15():1300183. PubMed ID: 38606181
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness analysis of amivantamab plus chemotherapy versus chemotherapy alone in NSCLC with EGFR Exon 20 insertions.
Yue P; Zhang M; Feng Y; Gao Y; Sun C; Chen P
Front Oncol; 2024; 14():1368804. PubMed ID: 38585010
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States.
Hu J; Ye Z; Xu Z; Hao Z; Wang Y
Front Public Health; 2022; 10():941738. PubMed ID: 36568792
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
